MétaCan
Menu
← Back to cohort
Record W4410064334 · doi:10.7759/cureus.83449

Comparative Cardiovascular Outcomes of Dapagliflozin Versus Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis

2025· review· en· W4410064334 on OpenAlexaff
Rhuna Dhana, Yousef Aqel, Anurag Rawat, Abdelaziz Maali Abusal, Nazish Munawar, Calvin R. Wei, Adil Amin

Bibliographic record

VenueCureus · 2025
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsAlberta HealthAlberta Health Services
Fundersnot available
KeywordsEmpagliflozinMedicineDapagliflozinType 2 diabetesMeta-analysisDiabetes mellitusBenzhydryl compoundsInternal medicineEndocrinology

Abstract

fetched live from OpenAlex

Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated significant cardiovascular benefits in patients with type 2 diabetes. However, head-to-head comparisons between dapagliflozin and empagliflozin, two widely prescribed SGLT2 inhibitors, remain limited. This meta-analysis aimed to directly compare the cardiovascular outcomes of these agents in patients with type 2 diabetes. We conducted a comprehensive literature search across multiple databases and included eight retrospective studies enrolling 280,617 patients (158,352 receiving empagliflozin and 122,265 receiving dapagliflozin). The primary outcome was major adverse cardiovascular events (MACE), with secondary outcomes including all-cause mortality, myocardial infarction, and stroke. Our pooled analysis revealed no significant difference in MACE risk between empagliflozin and dapagliflozin (RR: 1.04; 95% CI: 0.96 to 1.13). Similarly, no significant differences were observed for all-cause mortality (RR: 1.05; 95% CI: 0.96 to 1.15), myocardial infarction (RR: 1.04; 95% CI: 0.94 to 1.16), or stroke (RR: 1.00; 95% CI: 0.91 to 1.09). Subgroup analyses by gender, atherosclerotic cardiovascular disease, and chronic kidney disease status showed consistent results. However, in patients with heart failure, a trend toward reduced MACE risk was observed with empagliflozin (RR: 0.90; 95% CI: 0.82 to 1.00). Despite pharmacokinetic differences between these agents, our findings suggest comparable cardiovascular outcomes in patients with type 2 diabetes, with potentially enhanced benefits of empagliflozin in those with heart failure. However, due to lack of studies, this finding should be interpreted with caution. These results provide valuable insights for clinical decision-making when selecting SGLT2 inhibitors for cardiovascular risk reduction in diabetic patients. Further prospective studies are warranted to confirm these findings and explore potential mechanistic differences between these agents.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.014
metaresearch head score (Gemma)0.021
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: Meta-analysis
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.075

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0140.021
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0160.049
Bibliometrics0.0040.004
Science and technology studies0.0000.001
Scholarly communication0.0030.001
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.115
GPT teacher head0.357
Teacher spread0.242 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCureus→Same topicDiabetes Treatment and Management→French-language works237,207→